Wegovy Pill: What It Is, How Well It Works, and What It Costs
The FDA approved the Wegovy pill (oral semaglutide) on December 22, 2025, the first oral GLP-1 for obesity in the US. In OASIS 4, people lost about 17% of body weight at 64 weeks if all stayed on treatment (about 14% regardless of adherence) vs about 3% on placebo; self-pay starts at $149 per month.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
The Wegovy pill is an oral version of semaglutide, the same active ingredient as the Wegovy injection, made by Novo Nordisk. The FDA approved it on December 22, 2025, making it the first oral GLP-1 medicine for obesity in the US [2]. It is a once-daily tablet taken on an empty stomach in the morning, used along with a reduced-calorie diet and increased physical activity [1][2].
In the phase 3 OASIS 4 trial, people taking the 25 mg tablet lost about 17% of their body weight over 64 weeks if all patients stayed on treatment, versus about 3% on placebo. Looking at results regardless of whether people stayed on treatment, the figure was about 14% versus about 2% [2]. Self-pay pricing starts at $149 per month for the 1.5 mg starting dose, with the 9 mg and 25 mg doses at $299 per month under Novo’s standard self-pay offer [3][4]. Novo Nordisk expected a full US launch in early January 2026, with the 1.5 mg dose available in pharmacies and select telehealth providers at that time [2].
Is the Wegovy pill FDA approved?
Yes. The FDA approved once-daily Wegovy (semaglutide) tablets on December 22, 2025, and Novo Nordisk announced the approval the same day. It is the first oral GLP-1 medicine for obesity approved in the US [2]. The prescribing information for Wegovy covers both the injection and the tablets, with a revision date of June 2026; semaglutide’s initial US approval was in 2017 [1].
The tablets are produced in Novo Nordisk’s North Carolina facilities, and the company said at approval that supply was on hand [2]. The Wegovy brand has been prescribed for approximately 3.2 million people in the US [2].
What is the Wegovy pill approved to treat?
The tablets are approved for use with a reduced-calorie diet and increased physical activity for two purposes in adults [1][2]:
- Reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with established cardiovascular disease who also have obesity or overweight [1][2].
- Reducing excess body weight and keeping it off long term in adults with obesity, or adults with overweight who also have at least one weight-related health condition [2][5].
It is not known whether the tablets are safe and effective in people under 18 years old [2][5]. The label also carries a limitation of use: Wegovy tablets or injection are not recommended together with other semaglutide-containing products or any other GLP-1 receptor agonist [1].
What doses does the Wegovy pill come in?
The tablets come in four strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg [1]. Treatment starts at 1.5 mg once daily for 30 days, then follows an escalation schedule in the prescribing information, titrating every 30 days toward the maintenance dosage [1]. The recommended maintenance dosage of the tablets is 25 mg once daily [1][2].
One month is defined as one bottle of 30 tablets in Novo’s pricing programs [3][4]. For people with diabetes, the label says to monitor blood glucose before starting and during treatment [1]. Dose decisions belong to a prescriber — the escalation schedule is in the full prescribing information.
How do you take the Wegovy pill?
The label sets specific rules for taking the tablet [1]:
- Take it once daily, on an empty stomach, in the morning, with water — up to 4 ounces. No other liquids besides water.
- Swallow the tablet whole. Do not split, crush, chew, or dissolve it.
- Wait at least 30 minutes after taking it before eating food, drinking other beverages, or taking other oral medications.
Semaglutide delays stomach emptying, which can affect how other oral medications are absorbed. The label calls for extra clinical or laboratory monitoring when it is used with oral drugs that have a narrow therapeutic index or need monitoring [1].
How much weight can you lose on the Wegovy pill?
The approval was based on OASIS 4, a 64-week phase 3 trial in 307 adults with obesity (BMI of 30 or more) or overweight (BMI of 27 or more) plus at least one weight-related condition. People with diabetes were excluded. Participants were randomized 2:1 to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention, with a 12-week dose escalation and a 7-week off-treatment follow-up [2].
The results depend on how they are measured, and both figures matter [2]:
- If all patients stayed on treatment (the trial product estimand): about 17% average weight loss (16.6%) with the pill versus about 3% (2.7%) with placebo.
- Regardless of whether patients stayed on treatment (the treatment policy estimand): about 14% (13.6%) versus about 2% (2.4%).
Among those taking the pill, 76% lost 5% or more of their body weight, versus 31% on placebo. The pill group started at a baseline body weight of 235 lb and the placebo group at 231 lb [2].
Wegovy pill vs. injection: what’s different?
Both contain semaglutide, but the two forms are dosed and used differently. The injection is given once weekly, on the same day each week, at any time of day, with or without meals, injected under the skin in the abdomen, thigh, or upper arm. It starts at 0.25 mg weekly for 4 weeks and titrates every 4 weeks, with a usual maintenance dosage of 2.4 mg once weekly [1].
| Wegovy pill | Wegovy injection | |
|---|---|---|
| How often | Once daily | Once weekly |
| Strengths | 1.5, 4, 9, 25 mg tablets [1] | 0.25, 0.5, 1, 1.7, 2.4 mg pens and syringes; 7.2 mg (Wegovy HD) pen; 9.6 mg/3 mL FlexTouch pen delivering four 2.4 mg doses [1] |
| Usual maintenance | 25 mg once daily [1][2] | 2.4 mg once weekly [1] |
| Ages covered | Adults only [2][5] | Adults and pediatric patients 12 and older with obesity [1] |
| MASH indication | No | Yes — noncirrhotic MASH with F2–F3 fibrosis in adults, under accelerated approval [1] |
| Routine around the dose | Empty stomach, morning, up to 4 oz water, 30-minute wait [1] | Any time of day, with or without meals [1] |
The tablet and injection doses are separate scales — the sources do not support treating 25 mg daily and 2.4 mg weekly as equivalent or interchangeable. The prescribing information includes a section (2.5) on switching between the injection and tablets, and any switch belongs with a prescriber [1]. One safety note applies to the pen form only: never share a Wegovy FlexTouch pen between patients, even if the needle is changed [1].
How much does the Wegovy pill cost without insurance?
Novo’s self-pay pricing is available for local pharmacy pickup with a savings offer, or through home delivery from NovoCare Pharmacy [3][4]. These are promotional programs with eligibility limits, not guaranteed list prices — Novo states it can modify or cancel them at any time [3][4].
| Dose | Standard self-pay price |
|---|---|
| 1.5 mg | $149/mo [3][4] |
| 4 mg | $149/mo until August 31, 2026, then $199/mo [4][5]; Novo’s price guide lists 4 mg at $199/mo [3] |
| 9 mg | $299/mo [3] |
| 25 mg | $299/mo [3] |
For comparison, the Wegovy pen self-pay standard is $349 per month, with a limited-time $199 per month price for the first two fills of the 0.25 mg or 0.5 mg doses for new patients, running through December 31, 2026. Wegovy HD (7.2 mg pen) is $399 per month [3][4].
What does it cost with commercial insurance?
With commercial insurance and the savings offer, eligible patients pay as little as $25 per month, subject to a maximum savings of $100 per month [3][4]. The savings offer is limited to local pharmacy pickup, eligibility and restrictions apply, and government beneficiaries are excluded [3]. Wegovy is available at more than 70,000 US pharmacies plus NovoCare Pharmacy [5].
What about telehealth subscription pricing?
A multi-month subscription for eligible self-pay patients became available beginning March 31, 2026, through Ro, WeightWatchers, and LifeMD, with Hims & Hers, Sesame, and others to follow [5][6]. Longer subscriptions carry lower monthly prices [5]:
| Subscription | Pill, 9 mg and 25 mg | Pen, 0.25–2.4 mg |
|---|---|---|
| 3-month | $289/mo (saves $120/yr) | $329/mo (saves $240/yr) |
| 6-month | $269/mo (saves $360/yr) | $299/mo (saves $600/yr) |
| 12-month | $249/mo (saves $600/yr) | $249/mo (saves $1,200/yr) |
Under the subscription, the 1.5 mg and 4 mg pill doses remain $149 per month, with 4 mg at that price until August 31, 2026 [5][6]. Wegovy HD 7.2 mg is to be added to the subscription later [5][6]. Limited-time offers are separate from the subscriptions, and terms vary by telehealth platform — patients need to contact the provider directly for eligibility and full terms [5].
Does Medicare cover the Wegovy pill?
Eligible Medicare Part D enrollees can get Wegovy — pen or pill — for $50 per monthly supply under the Medicare GLP-1 Bridge, a time-limited demonstration running July 1, 2026 through December 31, 2027 [7][4]. A month is defined as one box of four pens or one bottle of 30 tablets [4].
Eligibility criteria are set by CMS, the program applies to a covered FDA-approved indication, and it is not a guarantee of coverage [4][7]. CMS handles centralized claims processing and payment to pharmacies [7].
Is the Wegovy pill the same as Rybelsus or the Ozempic tablet?
They share the active ingredient semaglutide, but they are different products with different approvals. Ozempic tablets come in 1.5 mg, 4 mg, and 9 mg; Rybelsus tablets come in 3 mg, 7 mg, and 14 mg [9]. Both are approved for blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk — not for weight loss [9].
Ozempic and Rybelsus tablets are not substitutable on a mg-to-mg basis [9]. They follow the same taking rules as the Wegovy pill — empty stomach in the morning, up to 4 ounces of water, swallow whole, 30-minute wait [9]. Ozempic tablets escalate from 1.5 mg for days 1–30 (a dose the label notes is not effective for glycemic control) to 4 mg for days 31–60, then 9 mg from day 61 if more glycemic control is needed [9]. The Wegovy pill adds a 25 mg strength that Ozempic tablets do not have [1][9].
How does the Wegovy pill compare with Foundayo (orforglipron)?
Foundayo, made by Eli Lilly, is a different medicine: a small-molecule, non-peptide oral GLP-1 approved on April 1, 2026 for adults with obesity or overweight with weight-related medical problems. It is taken once daily at any time of day, with no food or water restrictions [8].
In the ATTAIN-1 trial — 72 weeks, 3,127 participants — people on the highest dose who stayed on treatment lost an average of 27.3 lb (12.4%) versus 2.2 lb (0.9%) on placebo. Regardless of trial completion, the averages were 25 lb (11.1%) versus 5.3 lb (2.1%) [8]. These numbers come from a different trial with a different design and population than OASIS 4, so they cannot be compared head-to-head with the Wegovy pill’s results — no head-to-head trial has been published in these sources.
On price, Foundayo is $25 per month with a commercial savings card, self-pay starting at $149 per month for the lowest dose, and $50 per month for eligible Medicare Part D patients as soon as July 1, 2026. It is available via LillyDirect with free home delivery, with shipping beginning April 6, followed by retail pharmacies and telehealth [8]. It is not known whether Foundayo is safe and effective in children, and it should not be used with other GLP-1 receptor agonists [8].
What are the side effects and warnings?
In OASIS 4, common adverse reactions were similar to those seen in trials of the Wegovy 2.4 mg injection: nausea, diarrhea, and vomiting [2]. The label’s list of most common reactions (5% or more) also includes constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in people with type 2 diabetes, flatulence, gastroenteritis, GERD, and hair loss [1].
The label carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans [1]. Other warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or an insulin secretagogue, acute kidney injury from volume depletion, severe gastrointestinal reactions (not recommended in severe gastroparesis), hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications in type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation [1].
The prescribing information lists the Suicidal Behavior and Ideation warning as removed as of January 2026 [1], and the FDA issued a Drug Safety Communication requesting removal of that warning from GLP-1 receptor agonist medications [10]. Suspected adverse reactions can be reported to Novo Nordisk at 1-833-934-6891 or the FDA at 1-800-FDA-1088 [1].
Who should not take the Wegovy pill?
The tablets are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, and for anyone with a known serious hypersensitivity to semaglutide or any of the tablet’s ingredients [1].
Wegovy may cause fetal harm in pregnancy. Because semaglutide has a long half-life, the label says to discontinue it at least 2 months before a planned pregnancy [1][2]. Breastfeeding is not recommended during treatment with Wegovy tablets [1][2].
Before starting, the label says to tell the prescriber about pancreas or kidney problems, a history of diabetic retinopathy, planned surgery involving anesthesia or deep sedation, and all medicines being taken, including insulin or sulfonylureas [2].
Sources
- Novo Nordisk. Wegovy prescribing information.
- PR Newswire. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults.
- Novo Nordisk. Wegovy price guide.
- Novo Nordisk. Wegovy cost and coverage information.
- PR Newswire. Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy, offering savings of up to $1,200/year.
- Fierce Healthcare. Novo Nordisk launches discounted subscription program for Wegovy through telehealth providers. April 2, 2026.
- Centers for Medicare & Medicaid Services. Coming soon: CMS to provide $50 monthly access to GLP-1 medications for Medicare beneficiaries. May 6, 2026.
- Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
- Novo Nordisk. Ozempic tablets prescribing information.
- US Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
- NPR. Wegovy obesity pill now available at pharmacies. January 5, 2026.
Frequently asked questions
Is the Wegovy pill the same drug as the Wegovy shot?
Both contain semaglutide, made by Novo Nordisk, but they are different forms with separate dose scales. The pill is taken once daily and reaches a 25 mg maintenance dose; the shot is weekly with a usual 2.4 mg maintenance dose. The prescribing information has a section on switching between the two, which belongs with a prescriber.
Why is the pill dose 25 mg when the shot is 2.4 mg?
The tablet strengths run 1.5 mg to 25 mg and the injection strengths 0.25 mg to 2.4 mg, each with its own escalation schedule. No published source provides a conversion between them.
What happens if you eat too soon after taking it?
The label instructs waiting at least 30 minutes after the tablet before food, other beverages, or other oral medications, and taking it on an empty stomach with up to 4 ounces of water.
Can teenagers take the Wegovy pill?
It is not known whether Wegovy tablets are safe and effective in people under 18 years old. The Wegovy injection, by contrast, is approved for pediatric patients aged 12 and older with obesity. A prescriber can advise on what options exist for adolescents.
Can you switch from the injection to the pill?
The prescribing information includes a section (2.5) covering switching between Wegovy injection and tablets. The specific switching instructions are in the full prescribing information, and any switch should be handled by a prescriber rather than done on one's own.
What is the cheapest way to pay for the Wegovy pill without insurance?
Under Novo's self-pay programs, the 1.5 mg and 4 mg doses are $149 per month (4 mg until August 31, 2026). A 12-month telehealth subscription brings the 9 mg and 25 mg doses to $249 per month. These are promotional programs with eligibility limits that Novo may modify or cancel.
Does Medicare or Medicaid pay for the Wegovy pill?
Eligible Medicare Part D enrollees pay $50 per monthly supply under the Medicare GLP-1 Bridge, which runs July 1, 2026 through December 31, 2027. CMS sets the eligibility criteria, and it is not a guarantee of coverage.
Is the Wegovy pill the same as Rybelsus or the Ozempic tablet?
They all contain semaglutide, but the approvals differ. Ozempic tablets (1.5, 4, 9 mg) and Rybelsus (3, 7, 14 mg) are approved for type 2 diabetes, not weight loss, and are not substitutable mg-to-mg. The Wegovy pill is approved for weight management and cardiovascular risk reduction and adds a 25 mg strength.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.